Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
14
HCWB Quote, Financials, Valuation and Earnings
Last price:
$1.97
Seasonality move
:
-20.4%
Day range:
$1.95 - $2.11
52-week range:
$1.84 - $41.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.29x
P/B ratio:
5.96x
Volume:
15.7K
Avg. volume:
103.8K
1-year change:
-88.21%
Market cap:
$3.8M
Revenue:
$2.6M
EPS (TTM):
-$13.96
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HCWB
HCW Biologics Inc.
|
$7M | -- | 1541.65% | -- | $35.00 |
|
ALEC
Alector, Inc.
|
$3.5M | -$0.41 | -96.49% | -1693.03% | $2.05 |
|
COCP
Cocrystal Pharma, Inc.
|
-- | -$0.22 | -- | -43.93% | $8.00 |
|
GCTK
GlucoTrack, Inc.
|
-- | -- | -- | -- | -- |
|
NAKA
Kindly MD, Inc.
|
$400.2K | -$0.01 | -34.74% | -94.11% | $1.25 |
|
SLDB
Solid Biosciences, Inc.
|
-- | -$0.44 | -- | -49.66% | $15.23 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HCWB
HCW Biologics Inc.
|
$1.98 | $35.00 | $3.8M | -- | $0.00 | 0% | 7.29x |
|
ALEC
Alector, Inc.
|
$1.22 | $2.05 | $133.2M | -- | $0.00 | 0% | 1.77x |
|
COCP
Cocrystal Pharma, Inc.
|
$1.02 | $8.00 | $10.4M | -- | $0.00 | 0% | 8.34x |
|
GCTK
GlucoTrack, Inc.
|
$6.00 | -- | $171.9M | -- | $0.00 | 0% | 6.72x |
|
NAKA
Kindly MD, Inc.
|
$0.51 | $1.25 | $3.9M | -- | $0.00 | 0% | 14.30x |
|
SLDB
Solid Biosciences, Inc.
|
$5.77 | $15.23 | $449.5M | -- | $0.00 | 0% | 20.36x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HCWB
HCW Biologics Inc.
|
139.07% | -0.900 | 105.4% | 0.04x |
|
ALEC
Alector, Inc.
|
39.62% | 3.270 | 11.91% | 3.64x |
|
COCP
Cocrystal Pharma, Inc.
|
17.11% | 0.982 | 12.45% | 5.13x |
|
GCTK
GlucoTrack, Inc.
|
54.52% | 0.855 | 1.75% | 1.49x |
|
NAKA
Kindly MD, Inc.
|
29.88% | 41.625 | 2500.93% | 0.11x |
|
SLDB
Solid Biosciences, Inc.
|
9.15% | 2.940 | 4.57% | 6.50x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HCWB
HCW Biologics Inc.
|
-$170.8K | -$3.3M | -382.71% | -626.36% | -21064.74% | -$3.2M |
|
ALEC
Alector, Inc.
|
$928K | -$37.7M | -81.03% | -114.8% | -1156.69% | -$32.5M |
|
COCP
Cocrystal Pharma, Inc.
|
-$13K | -$2.1M | -94.47% | -113.69% | -- | -$1.6M |
|
GCTK
GlucoTrack, Inc.
|
-$9K | -$4.3M | -2079.63% | -- | -- | -$4.7M |
|
NAKA
Kindly MD, Inc.
|
-$6.1M | -$10.4M | -64.63% | -91.57% | -2680.45% | -$692.1M |
|
SLDB
Solid Biosciences, Inc.
|
-$376K | -$48.1M | -70.08% | -77.74% | -- | -$33.6M |
HCW Biologics Inc. vs. Competitors
-
Which has Higher Returns HCWB or ALEC?
Alector, Inc. has a net margin of -29194.23% compared to HCW Biologics Inc.'s net margin of -1063.41%. HCW Biologics Inc.'s return on equity of -626.36% beat Alector, Inc.'s return on equity of -114.8%.
Company Gross Margin Earnings Per Share Invested Capital HCWBHCW Biologics Inc.-1094.87% -$2.02 $5.4M ALECAlector, Inc.28.47% -$0.34 $95.6M -
What do Analysts Say About HCWB or ALEC?
HCW Biologics Inc. has a consensus price target of $35.00, signalling upside risk potential of 1667.68%. On the other hand Alector, Inc. has an analysts' consensus of $2.05 which suggests that it could grow by 68.03%. Given that HCW Biologics Inc. has higher upside potential than Alector, Inc., analysts believe HCW Biologics Inc. is more attractive than Alector, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HCWBHCW Biologics Inc.0 0 0 ALECAlector, Inc.1 6 1 -
Is HCWB or ALEC More Risky?
HCW Biologics Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alector, Inc. has a beta of 0.667, suggesting its less volatile than the S&P 500 by 33.287%.
-
Which is a Better Dividend Stock HCWB or ALEC?
HCW Biologics Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alector, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HCW Biologics Inc. pays -- of its earnings as a dividend. Alector, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HCWB or ALEC?
HCW Biologics Inc. quarterly revenues are $15.6K, which are smaller than Alector, Inc. quarterly revenues of $3.3M. HCW Biologics Inc.'s net income of -$4.6M is higher than Alector, Inc.'s net income of -$34.7M. Notably, HCW Biologics Inc.'s price-to-earnings ratio is -- while Alector, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HCW Biologics Inc. is 7.29x versus 1.77x for Alector, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HCWBHCW Biologics Inc.7.29x -- $15.6K -$4.6M ALECAlector, Inc.1.77x -- $3.3M -$34.7M
-
Which has Higher Returns HCWB or COCP?
Cocrystal Pharma, Inc. has a net margin of -29194.23% compared to HCW Biologics Inc.'s net margin of --. HCW Biologics Inc.'s return on equity of -626.36% beat Cocrystal Pharma, Inc.'s return on equity of -113.69%.
Company Gross Margin Earnings Per Share Invested Capital HCWBHCW Biologics Inc.-1094.87% -$2.02 $5.4M COCPCocrystal Pharma, Inc.-- -$0.19 $9.3M -
What do Analysts Say About HCWB or COCP?
HCW Biologics Inc. has a consensus price target of $35.00, signalling upside risk potential of 1667.68%. On the other hand Cocrystal Pharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 684.31%. Given that HCW Biologics Inc. has higher upside potential than Cocrystal Pharma, Inc., analysts believe HCW Biologics Inc. is more attractive than Cocrystal Pharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HCWBHCW Biologics Inc.0 0 0 COCPCocrystal Pharma, Inc.1 0 0 -
Is HCWB or COCP More Risky?
HCW Biologics Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cocrystal Pharma, Inc. has a beta of 1.045, suggesting its more volatile than the S&P 500 by 4.52%.
-
Which is a Better Dividend Stock HCWB or COCP?
HCW Biologics Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cocrystal Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HCW Biologics Inc. pays -- of its earnings as a dividend. Cocrystal Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HCWB or COCP?
HCW Biologics Inc. quarterly revenues are $15.6K, which are larger than Cocrystal Pharma, Inc. quarterly revenues of --. HCW Biologics Inc.'s net income of -$4.6M is lower than Cocrystal Pharma, Inc.'s net income of -$2M. Notably, HCW Biologics Inc.'s price-to-earnings ratio is -- while Cocrystal Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HCW Biologics Inc. is 7.29x versus 8.34x for Cocrystal Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HCWBHCW Biologics Inc.7.29x -- $15.6K -$4.6M COCPCocrystal Pharma, Inc.8.34x -- -- -$2M
-
Which has Higher Returns HCWB or GCTK?
GlucoTrack, Inc. has a net margin of -29194.23% compared to HCW Biologics Inc.'s net margin of --. HCW Biologics Inc.'s return on equity of -626.36% beat GlucoTrack, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HCWBHCW Biologics Inc.-1094.87% -$2.02 $5.4M GCTKGlucoTrack, Inc.-- -$4.64 $6M -
What do Analysts Say About HCWB or GCTK?
HCW Biologics Inc. has a consensus price target of $35.00, signalling upside risk potential of 1667.68%. On the other hand GlucoTrack, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that HCW Biologics Inc. has higher upside potential than GlucoTrack, Inc., analysts believe HCW Biologics Inc. is more attractive than GlucoTrack, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HCWBHCW Biologics Inc.0 0 0 GCTKGlucoTrack, Inc.0 0 0 -
Is HCWB or GCTK More Risky?
HCW Biologics Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GlucoTrack, Inc. has a beta of 0.300, suggesting its less volatile than the S&P 500 by 70.003%.
-
Which is a Better Dividend Stock HCWB or GCTK?
HCW Biologics Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GlucoTrack, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HCW Biologics Inc. pays -- of its earnings as a dividend. GlucoTrack, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HCWB or GCTK?
HCW Biologics Inc. quarterly revenues are $15.6K, which are larger than GlucoTrack, Inc. quarterly revenues of --. HCW Biologics Inc.'s net income of -$4.6M is lower than GlucoTrack, Inc.'s net income of -$4.2M. Notably, HCW Biologics Inc.'s price-to-earnings ratio is -- while GlucoTrack, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HCW Biologics Inc. is 7.29x versus 6.72x for GlucoTrack, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HCWBHCW Biologics Inc.7.29x -- $15.6K -$4.6M GCTKGlucoTrack, Inc.6.72x -- -- -$4.2M
-
Which has Higher Returns HCWB or NAKA?
Kindly MD, Inc. has a net margin of -29194.23% compared to HCW Biologics Inc.'s net margin of -22162.75%. HCW Biologics Inc.'s return on equity of -626.36% beat Kindly MD, Inc.'s return on equity of -91.57%.
Company Gross Margin Earnings Per Share Invested Capital HCWBHCW Biologics Inc.-1094.87% -$2.02 $5.4M NAKAKindly MD, Inc.-1565.61% -$0.42 $681.1M -
What do Analysts Say About HCWB or NAKA?
HCW Biologics Inc. has a consensus price target of $35.00, signalling upside risk potential of 1667.68%. On the other hand Kindly MD, Inc. has an analysts' consensus of $1.25 which suggests that it could grow by 144.95%. Given that HCW Biologics Inc. has higher upside potential than Kindly MD, Inc., analysts believe HCW Biologics Inc. is more attractive than Kindly MD, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HCWBHCW Biologics Inc.0 0 0 NAKAKindly MD, Inc.1 0 0 -
Is HCWB or NAKA More Risky?
HCW Biologics Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kindly MD, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HCWB or NAKA?
HCW Biologics Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kindly MD, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HCW Biologics Inc. pays -- of its earnings as a dividend. Kindly MD, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HCWB or NAKA?
HCW Biologics Inc. quarterly revenues are $15.6K, which are smaller than Kindly MD, Inc. quarterly revenues of $388.2K. HCW Biologics Inc.'s net income of -$4.6M is higher than Kindly MD, Inc.'s net income of -$86M. Notably, HCW Biologics Inc.'s price-to-earnings ratio is -- while Kindly MD, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HCW Biologics Inc. is 7.29x versus 14.30x for Kindly MD, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HCWBHCW Biologics Inc.7.29x -- $15.6K -$4.6M NAKAKindly MD, Inc.14.30x -- $388.2K -$86M
-
Which has Higher Returns HCWB or SLDB?
Solid Biosciences, Inc. has a net margin of -29194.23% compared to HCW Biologics Inc.'s net margin of --. HCW Biologics Inc.'s return on equity of -626.36% beat Solid Biosciences, Inc.'s return on equity of -77.74%.
Company Gross Margin Earnings Per Share Invested Capital HCWBHCW Biologics Inc.-1094.87% -$2.02 $5.4M SLDBSolid Biosciences, Inc.-- -$0.48 $239.9M -
What do Analysts Say About HCWB or SLDB?
HCW Biologics Inc. has a consensus price target of $35.00, signalling upside risk potential of 1667.68%. On the other hand Solid Biosciences, Inc. has an analysts' consensus of $15.23 which suggests that it could grow by 163.97%. Given that HCW Biologics Inc. has higher upside potential than Solid Biosciences, Inc., analysts believe HCW Biologics Inc. is more attractive than Solid Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HCWBHCW Biologics Inc.0 0 0 SLDBSolid Biosciences, Inc.9 0 0 -
Is HCWB or SLDB More Risky?
HCW Biologics Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Solid Biosciences, Inc. has a beta of 2.975, suggesting its more volatile than the S&P 500 by 197.54%.
-
Which is a Better Dividend Stock HCWB or SLDB?
HCW Biologics Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solid Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HCW Biologics Inc. pays -- of its earnings as a dividend. Solid Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HCWB or SLDB?
HCW Biologics Inc. quarterly revenues are $15.6K, which are larger than Solid Biosciences, Inc. quarterly revenues of --. HCW Biologics Inc.'s net income of -$4.6M is higher than Solid Biosciences, Inc.'s net income of -$45.8M. Notably, HCW Biologics Inc.'s price-to-earnings ratio is -- while Solid Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HCW Biologics Inc. is 7.29x versus 20.36x for Solid Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HCWBHCW Biologics Inc.7.29x -- $15.6K -$4.6M SLDBSolid Biosciences, Inc.20.36x -- -- -$45.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
